Biotechnology company
Appears in 1 story
Acquisition target; to be folded into Lilly
Eli Lilly agreed to buy Merida Biosciences for up to $2.875 billion. The deal adds a platform that destroys the specific antibodies driving autoimmune disease instead of broadly suppressing the immune system. Merida's lead drug, MER511, is in early human testing for Graves' disease and thyroid eye disease.
Updated 12 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
